Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

18.77

P/S

3.95

EPS

0.51

Div Yield, %

1.04%

Shrs. gr., 5y

0.97%

Rev. gr., 5y

9.70%

Revenues

3.92b

-0.20%

Net income

826m

CFO

1.50b

-7.28%

Dividend

Jul 08, 20240.1 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.

URL

https://www.nkf-pharma.com/

IPO date

Jul 19, 2017

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT